Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CANF logo CANF
Upturn stock ratingUpturn stock rating
CANF logo

Can Fite Biopharma Ltd ADR (CANF)

Upturn stock ratingUpturn stock rating
$1.05
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CANF (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $7.25

1 Year Target Price $7.25

Analysts Price Target For last 52 week
$7.25Target price
Low$0.98
Current$1.05
high$4.69

Analysis of Past Performance

Type Stock
Historic Profit -44.59%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 13.39M USD
Price to earnings Ratio -
1Y Target Price 7.25
Price to earnings Ratio -
1Y Target Price 7.25
Volume (30-day avg) 2
Beta 0.23
52 Weeks Range 0.98 - 4.69
Updated Date 06/29/2025
52 Weeks Range 0.98 - 4.69
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1127.37%

Management Effectiveness

Return on Assets (TTM) -53.18%
Return on Equity (TTM) -134.94%

Valuation

Trailing PE -
Forward PE 2.97
Enterprise Value 7006852
Price to Sales(TTM) 19.87
Enterprise Value 7006852
Price to Sales(TTM) 19.87
Enterprise Value to Revenue 10.4
Enterprise Value to EBITDA 0.1
Shares Outstanding 12877200
Shares Floating 3105367426
Shares Outstanding 12877200
Shares Floating 3105367426
Percent Insiders -
Percent Institutions 1.17

Analyst Ratings

Rating 2
Target Price 7.25
Buy -
Strong Buy 2
Buy -
Strong Buy 2
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Can Fite Biopharma Ltd ADR

stock logo

Company Overview

overview logo History and Background

Can-Fite BioPharma Ltd. was founded in 2000 and is an Israeli biopharmaceutical company focused on developing and commercializing novel treatments for liver, inflammatory, and autoimmune diseases. They are traded on the NYSE American as CANF.

business area logo Core Business Areas

  • Liver Diseases: Development of Piclidenoson and Namodenoson for the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
  • Inflammatory Diseases: Research and development of Piclidenoson for psoriasis and rheumatoid arthritis.

leadership logo Leadership and Structure

Dr. Pnina Fishman is the CEO. The company has a board of directors and various management positions overseeing research, development, and operations.

Top Products and Market Share

overview logo Key Offerings

  • Piclidenoson: An A3 adenosine receptor agonist (A3AR) being developed for psoriasis and rheumatoid arthritis. It is in Phase III trials. Market share data is unavailable. Competitors include companies developing similar therapies such as Amgen (AMGN) and AbbVie (ABBV).
  • Namodenoson: An A3AR agonist being developed for NASH and HCC. It is in Phase II trials. Market share data is unavailable. Competitors include Gilead Sciences (GILD) and Intercept Pharmaceuticals (ICPT) (acquired by Alfasigma).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and regulated. It's marked by high R&D costs and lengthy clinical trials. Success depends on regulatory approvals, patent protection, and commercialization.

Positioning

Can-Fite is a smaller biopharmaceutical company focusing on A3AR agonists. Their competitive advantage lies in their proprietary technology and potential to address unmet medical needs in liver and inflammatory diseases.

Total Addressable Market (TAM)

The TAM for NASH and HCC is estimated to be billions of dollars. Can-Fite is positioned to capture a portion of this market if their drugs are approved and successfully commercialized. TAM for Psoriasis and rheumatoid arthritis also estimates in the billions.

Upturn SWOT Analysis

Strengths

  • Proprietary A3AR agonist technology platform
  • Promising clinical trial results for Piclidenoson and Namodenoson
  • Experienced management team
  • Focus on unmet medical needs

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Dependence on successful clinical trial outcomes and regulatory approvals
  • Lack of established commercial infrastructure
  • Relatively small size of the company

Opportunities

  • Potential to partner with larger pharmaceutical companies for development and commercialization
  • Expansion into new indications for A3AR agonists
  • Growing market for NASH and HCC treatments
  • Positive clinical trial data could attract investors

Threats

  • Failure to obtain regulatory approvals
  • Competition from other companies developing similar treatments
  • Unfavorable clinical trial results
  • Changes in the regulatory environment
  • Difficulty in securing financing

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • ABBV
  • AMGN
  • ICPT

Competitive Landscape

Can-Fite faces intense competition from larger, more established pharmaceutical companies. Its success depends on differentiating its products and demonstrating superior efficacy and safety.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited as the company is primarily focused on R&D.

Future Projections: Future growth depends on the successful development and commercialization of Piclidenoson and Namodenoson. Analyst estimates vary widely and should be reviewed carefully. Growth projections are highly speculative.

Recent Initiatives: Recent initiatives include advancing Piclidenoson and Namodenoson through clinical trials, seeking partnerships, and securing financing.

Summary

Can-Fite Biopharma is a development-stage company with potential in treating liver and inflammatory diseases through its A3AR agonist technology. The company's strengths include its proprietary technology and promising clinical trial results. However, it faces challenges due to limited financial resources, reliance on clinical trial success, and competition from larger pharmaceutical companies. Can-Fite needs to focus on securing partnerships and advancing its clinical programs to drive future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings, Press releases, Analyst reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available information. Clinical trial outcomes are inherently uncertain.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Can Fite Biopharma Ltd ADR

Exchange NYSE MKT
Headquaters -
IPO Launch date 2012-11-06
CEO and Chief Financial & Operating Officer Mr. Motti Farbstein
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.